

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199747746 B2
(10) Patent No. 716208

(54) Title
Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis

(51)⁶ International Patent Classification(s)
A61K 007/00

(21) Application No: 199747746 (22) Application Date: 1997.09.16

(87) WIPO No: WO98/13009

(30) Priority Data

(31) Number 19639818	(32) Date 1996.09.27	(33) Country DE
(43) Publication Date : 1998.04.17		
(43) Publication Journal Date : 1998.06.11		
(44) Accepted Journal Date : 2000.02.24		

(71) Applicant(s)
Hoechst Aktiengesellschaft


(72) Inventor(s)
Manfred Bohn; Karl Theodor Kraemer; Astrid Markus

(74) Agent/Attorney
WATERMARK PATENT and TRADEMARK ATTORNEYS, Locked Bag 5, HAWTHORN VIC 3122

OPI DATE 17/04/98 APPLN. ID 47746/97
AOJP DATE 11/06/98 PCT NUMBER PCT/EP97/05070



AU9747746


<p>(51) Internationale Patentklassifikation ⁶:</p> <p>A61K 7/00</p>		<p>(11) Internationale Veröffentlichungsnummer: WO 98/13009</p> <p>(43) Internationales Veröffentlichungsdatum: 2. April 1998 (02.04.98)</p>
<p>(21) Internationales Aktenzeichen: PCT/EP97/05070</p> <p>(22) Internationales Anmeldedatum: 16. September 1997 (16.09.97)</p> <p>(30) Prioritätsdaten: 196 39 818.5 27. September 1996 (27.09.96) DE</p> <p>(71) Anmelder (für alle Bestimmungsstaaten ausser US): HOECHST AKTIENGESELLSCHAFT [DE/DE]; Brüningstrasse 50, D-65929 Frankfurt am Main (DE).</p> <p>(72) Erfinder; und</p> <p>(75) Erfinder/Anmelder (nur für US): BOHN, Manfred [DE/DE]; Schweriner Weg 10, D-65719 Hofheim (DE), KRAEMER, Karl, Theodor [DE/DE]; Im Buchenhain 37, D-63225 Langen (DE), MARKUS, Astrid [DE/DE]; Sulzbacher Strasse 6, D-65835 Liederbach (DE).</p>		<p>(81) Bestimmungsstaaten: AU, BG, BR, BY, CA, CN, CZ, HU, ID, IL, JP, KR, MX, NO, NZ, PL, RO, RU, SG, SI, TR, UA, US, YU, europäisches Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Veröffentlicht <i>Ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts.</i></p>
<p>(54) Titel: USE OF 1-HYDROXY-2-PYRIDONE FOR THE TREATMENT OF SEBORRHEIC DERMATITIS</p> <p>(54) Bezeichnung: VERWENDUNG VON 1-HYDROXY-2-PYRIDONEN ZUR BEHANDLUNG DER SEBORRHOISCHEN DERMATITIS</p> <p>(57) Abstract</p> <p>Compounds of the formula (I) are suitable for the production of pharmaceuticals to treat seborrheic dermatitis.</p> <p>(57) Zusammenfassung</p> <p>Verbindungen der Formel (I) eignen sich zur Herstellung von Arzneimitteln zur Behandlung der Seborrhoischen Dermatitis.</p> <p style="text-align: center;"></p>		

96/F 258 WO

Abstract

Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis

Compounds of the formula I



are suitable for the production of pharmaceuticals for the treatment of seborrheic dermatitis.



Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis

Seborrheic dermatitis is understood as meaning a disorder of the scalp which differs from simple dandruff by the presence of erythema as a sign

5 of inflammation, by the greater degree of scaling with occasional itching and burning, and by the occurrence of eczematous changes to other body sites. It can occur in the form of patches, but also more frequently affects the whole scalp and often includes, beyond the hairline, the forehead, around the neck and the ears. In severe cases, the scalp can have a
10 secondary infection, and the changes can then exhibit a spongy consistency, vesicle and crust formation and can weep.

Seborrheic dermatitis frequently occurs even in infancy and usually remits spontaneously at an age of 8-12 months. The scalp changes consisting of

15 erythema, scaling and occasionally vesicles and crusts in infants can regress spontaneously within a few weeks, intermittently reoccur or persist during the entire childhood. They are frequently combined with a similar process around the eyelids, nose and ears. Later, the condition usually occurs after puberty and can last for the whole life or even increase in
20 strength. Approximately 1-3% of the population are affected by this illness.

It is known that 1-hydroxy-2-pyridones and their salts exhibit activity against normal dandruff which is characterized by a clinically noninflammatory scaling of the scalp occurring in nearly all people (DE 22 34 009).

25 The most promising type of treatment of seborrheic dermatitis until now was the topical application of corticosteroid preparations, but more recently topical therapy with antimycotic substances has gained importance.

30 While corticosteroid preparations display their activity exclusively via an effect on the inflammatory process, the antimycotic substances such as ketoconazole are active exclusively against the yeast fungi of the strain *Pityrosporum* which is assumed to be the cause of seborrheic dermatitis. The 1-hydroxy-2-pyridones according to the invention, however, combine
35 the properties of both classes of substance in one substance and exhibit both antiinflammatory action and antimycotic activity against *Pityrosporum* strains.




In comparison to ketoconazole, the substances according to the invention - even after only a short topical contact time - concentrate rapidly in the skin layers which are relevant for fungal growth and thus contribute to a rapid cure.

5 While ketoconazole is inactive *in vitro* against gram-positive bacteria (Kinsman et al., *J. Med. Microbiol.* (1983) 16, No. 2, IV), the hydroxy-pyridones according to the invention exhibit activity against gram-positive and gram-negative aerobic and anaerobic bacteria (Dittmar et al.,
 10 *Arzneim.-Forschung*, (1981) 31 (II), No. 8a, pp. 1317-1322). With respect to the treatment of secondarily infected cases, this is an extremely important finding.

15 Compared with ketoconazole, the compounds used according to the invention furthermore have very crucial advantages with respect to their processing possibilities in pharmaceutical preparations. On account of their solubility in water, alcohols and aqueous-alcoholic solutions, the preparation of hair lotions and transparent gel preparations is possible without problems.


20 The preparations according to the invention can also be employed for the treatment of *Pityriasis versicolor*, a superficial, noninflammatory skin fungus disorder on the trunk.

25 The invention therefore relates to the use of 1-hydroxy-2-pyridones of the formula I



30 in which R¹, R² and R³, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and
 R⁴ is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II





where

X is S or O,

5 Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine,

Z is a single bond or the bivalent radicals O, S, -CR²- (R = H or (C₁-C₄)-alkyl) or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a

10 chain, where - if the radicals contain 2 or more oxygen and/or sulfur atoms - the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C₁-C₄)-alkyl groups,

15 Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C₁-C₄)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form,

for the production of a pharmaceutical for the treatment of seborrhic dermatitis.

20 The invention also relates to a method of treatment of seborrhic dermatitis comprising administration of the above defined 1-hydroxy-2-pyridones of formula I.

In the radicals "Z", the carbon chain members are preferably CH₂ groups. If the CH₂ groups are substituted by C₁-C₄-alkyl groups, CH₃ and C₂H₅ are preferred substituents. Exemplary radicals "Z" are:

25 -O-, -S-, -CH₂-, -(CH₂)_m-, (m = 2-10), -C(CH₃)₂-, -CH₂O-, -OCH₂-, -CH₂S-,
 -SCH₂-, -SCH(C₂H₅)-, -CH=CH-CH₂O-, -O-CH₂-CH=CH-CH₂O-,
 -OCH₂-CH₂O-, -OCH₂-CH₂CH₂O-, -SCH₂CH₂CH₂S-,
 -SCH₂CH₂CH₂CH₂O-, -SCH₂CH₂OCH₂CH₂O-,
 -SCH₂CH₂OCH₂CH₂O-CH₂CH₂S- or -S-CH₂-C(CH₃)₂-CH₂-S-.

30 The radical "S" is a sulfur atom, the radical "O" is an oxygen atom. The term "Ar" denotes phenyl or fused systems such as naphthyl, tetrahydro-naphthyl and indenyl, and also isolated systems as such, which are derived from biphenyl, diphenylalkanes, diphenyl ethers and diphenyl thioethers.



In the formula I, the hydrocarbon radical R^4 is an alkyl or cyclohexyl radical which can also be bonded to the pyridone ring via a methylene or ethylene group or can contain an endomethyl group. R^4 can also be an aromatic radical which, however, is preferably bonded to the pyridone radical via at least one aliphatic carbon atom.

Important representatives of the class of compounds characterized by the formula I are:

- 10 6-[4-(4-chlorophenoxy)phenoxyethyl]-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorophenoxy)phenoxyethyl]-1-hydroxy-4-methyl-2-pyridone, 6-(biphenyl-4-oxyethyl)-1-hydroxy-4-methyl-2-pyridone, 6-(4-benzyl-phenoxyethyl)-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl-oxy)phenoxyethyl]-1-hydroxy-4-methyl-2-pyridone, 6-[4-(4-chlorophenoxy)phenoxyethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl)phenoxyethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-cinnamylxyloxy]phenoxyethyl]-1-hydroxy-4-methyl-2-pyridone, 1-hydroxy-4-methyl-6-[4-(4-trifluoromethylphenoxy)phenoxyethyl]-2-pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, 1-hydroxy-4-methyl-6-n-hexyl-, -6-isohexyl-, -6-n-heptyl- or -6-isoheptyl-2-pyridone, 1-hydroxy-4-methyl-6-octyl- or -6-isoctyl-2-pyridone, in particular 1-hydroxy-4-methyl-6-cyclohexylmethyl- or -6-cyclohexylethyl-2-pyridone, where the cyclohexyl radical can in each case also carry a methyl radical, 1-hydroxy-4-methyl-6-(2-bicyclo[2,2,1]heptyl)-2-pyridone, 1-hydroxy-3,4-dimethyl-6-benzyl- or -6-dimethylbenzyl-2-pyridone or 1-hydroxy-4-methyl-6-(β -phenylethyl)-2-pyridone.

The term "saturated" in this case designates those radicals which contain no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds.

- 30 The abovementioned compounds of the formula I can be employed either in free form or as salts, use in free form is preferred.

- 35 If organic bases are used, poorly volatile bases are preferably employed, for example low molecular weight alkanolamines such as ethanamine, diethanamine, N-ethylethanamine, N-methyldiethanamine, triethanolamine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylamino-propanol, 2-amino-2-methylpropanediol, triisopropanolamine. Further



poorly volatile bases which may be mentioned are, for example, ethylenediamine, hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, N,N-dimethyldodecylamine, stearylamine, oleylamine, benzylamine, dibenzylamine, N-ethylbenzylamine, dimethylstearylamine, N-methylmorpholine, N-methylpiperazine, 4-methylcyclohexylamine, N-hydroxyethylmorpholine. The salts of quaternary ammonium hydroxides such as trimethylbenzylammonium hydroxide, tetramethylammonium hydroxide or tetraethylammonium hydroxide can also be used, furthermore

5 guanidine and its derivatives, in particular its alkylation products. However, it is also possible to employ as salt-forming agents, for example, low molecular weight alkylamines such as methylamine, ethylamine or triethylamine. Suitable salts for the compounds to be employed according to the invention are also those with inorganic cations, for example alkali

10 metal salts, in particular sodium, potassium or ammonium salts, alkaline earth metal salts such as, in particular, the magnesium or calcium salts, as well as salts with bi- or tetravalent cations, for example the zinc, aluminum or zirconium salt.

15 The active compounds to be employed in the preparations of the compound of the formula I can be prepared, for example, according to processes given in US 2 540 218.

20 For the use according to the invention of the compounds mentioned, liquid to semisolid pharmaceutical preparations, in particular hair lotions, shampoos, liquid soaps, as well as cream, ointment and gel preparations, are suitable.

25 In this case, these are always preparations which, depending on their actual intended use, are applied to the skin and/or to the scalp for a shorter or longer time. Due to the addition of the compounds according to the invention, an effective treatment of the seborrheic dermatitis is brought about.

30 If the preparations according to the invention are present as shampoo, they can be in clear liquid or opaque liquid form, in cream form or even gelatinous. The surfactants on which these shampoos are based can be of



anionic, cationic, nonionic or amphoteric nature and can also be present as a combination of these substances.

Preferably, however, anionic surfactants are employed on their own or as a 5 mixture with other anionic surfactants as base surfactants - if appropriate with addition of amphoteric surfactants as cosurfactant.

As the sole detergent substances, amphoteric surfactants are virtually 10 insignificant, since their foaming behavior, thickenability and partly also skin and eye mucous membrane tolerability are only moderate. In combination with various anionic surfactants, however, precisely these properties are synergistically improved. This explains the relatively great importance of the amphoteric surfactants for the optimization of anionic shampoo bases.

15 Nonionic surfactants can also be employed as cosurfactants.

Examples of anionic detergent substances of this type which may be mentioned are: (C₁₀-C₂₀)-alkyl- and -alkylenecarboxylates, alkyl ether 20 carboxylates, fatty alcohol sulfates, fatty alcohol ether sulfates, alkylolamide sulfates and sulfonates, fatty acid alkylamide polyglycol ether sulfates, alkanesulfonates and hydroxyalkanesulfonates, olefinsulfonates, acyl esters of isothionates, α -sulfophatty acid esters, alkylbenzosulfonates, 25 alkylphenol glycol ether sulfonates, sulfosuccinates, sulfosuccinic acid hemiesters and diesters, fatty alcohol ether phosphates, protein-fatty acid condensation products, alkylmonoglyceride sulfates and sulfonates, alkylglyceride ether sulfonates, fatty acid methyltaurides, fatty acid sarcosinates or sulforicinoleates. These compounds and their mixtures are used in the form of their water-soluble or water-dispersible salts, for 30 example the sodium, potassium, magnesium, ammonium, mono-, di- and triethanolammonium as well as analogous alkylolammonium salts.

Examples of amphoteric surfactants which can be added to the shampoos are: N-((C₁₂-C₁₈)-alkyl)- β -aminopropionates and N-((C₁₂-C₁₈)-alkyl)-35 β -iminodipropionates as alkali metal and mono-, di- and trialkylolammonium salts; N-acylamidoalkyl-N,N-dimethylacetobetaine, preferably N-((C₈-C₁₈)-acyl)amidopropyl-N,N-dimethylacetobetaine; (C₁₂-C₁₈)-alkyl-dimethylsulfopropylbetaine; amphoteric surfactants based on imidazoline



(trade name: Miranol[®], Steinapon[®]), preferably the sodium salt of 1-(β -carboxymethoxyethyl)-1-(carboxymethyl)-2-laurylimidazolinium; amine oxides, e.g. (C₁₂-C₁₈)-alkyldimethylamine oxide or fatty acid amidoalkyldimethylamine oxide.

5 Suitable nonionic surfactants which can be employed as detergent substances are, for example: fatty alcohol ethoxylates (alkyl polyethylene glycols); alkylphenol polyethylene glycols; alkylmercaptan polyethylene glycols; fatty amine ethoxylates (alkylamino polyethylene glycols); fatty acid 10 ethoxylates (acyl polyethylene glycols), polypropylene glycol ethoxylates (Pluronic[®]); fatty acid alkylolamides (fatty acid amide polyethylene glycols); sucrose esters; alkyl polyglucosides; sorbitol esters and polyglycol ether.

Suitable cationic surfactants are, for example, quaternary ammonium salts 15 such as di-((C₁₀-C₂₄)-alkyl)dimethylammonium chloride or bromide, preferably di-((C₁₂-C₁₈)-alkyl)dimethylammonium chloride or bromide; (C₁₀-C₂₄)-alkyltrimethylammonium chloride or bromide, preferably cetyltrimethylammonium chloride or bromide and (C₂₀-C₂₂)-alkyltrimethylammonium 20 chloride or bromide; (C₁₀-C₂₄)-alkyldimethylbenzylammonium chloride or bromide; preferably (C₁₂-C₁₈)-alkyldimethylbenzylammonium chloride; N-((C₁₀-C₁₈)-alkyl)pyridinium chloride or bromide, preferably N-((C₁₂-C₁₆)-alkyl)pyridinium chloride or bromide; N-((C₁₀-C₁₈)-alkyl)isoquinolinium 25 chloride, bromide or monoalkylsulfate; N-((C₁₂-C₁₈)-alkyl)colaminoformylmethylpyridinium chloride; N-((C₁₂-C₁₈)-alkyl)-N-methylmorpholinium chloride, bromide or monoalkylsulfate, N-((C₁₂-C₁₈)-alkyl)-N-ethylmorpholinium chloride, bromide or monoalkylsulfate; (C₁₆-C₁₈)-alkylpentaoxyethylammonium chloride; diisobutylphenoxyethoxyethyldimethylbenzylammonium chloride; salts of N,N-diethylaminoethylstearylamine and 30 -oleylamide with hydrochloric acid, acetic acid, lactic acid, citric acid, phosphoric acid; N-acylamidoethyl-N,N-diethyl-N-methylammonium chloride, bromide or monoalkylsulfate and N-acylamidoethyl-N,N-diethyl-N-benzylammonium chloride, bromide or monoalkylsulfate, where acyl is preferably stearyl or oleyl.

35 The preparations according to the invention can additionally contain further additives, e.g. aromatic substances, colorants, opacifiers and pearl luster



agents, for example esters of fatty acids and polyols, magnesium and zinc salts of fatty acids, dispersions based on copolymers, thickeners such as sodium, potassium or ammonium chloride, sodium sulfate, fatty acid alkylolamides, cellulose derivatives of natural gums, collagen hydrolyzates,

5 furthermore fats, oils, fatty alcohols, silicones, substances having a keratolytic and keratoplastic action, for example sulfur, salicylic acid or enzymes.

The shampoos are prepared in a manner known per se by mixing together of the individual components and a further processing - if necessary -

10 suited to the particular type of preparation. Some of these various possible preparations are described by way of example in the working examples.

The preparations according to the invention can also be present in the form of aqueous and aqueous-alcoholic hair lotions, and also those in gel form

15 and in aerosol form as spray or foam. Alcohols employed are preferably ethanol and isopropyl alcohol.

Further preparations which may be mentioned in which the 1-hydroxy-2-pyridones can be used according to the invention are, for example,

20 cream and ointment preparations, products which are primarily used for the treatment of hairless head and body parts.

The preparation of all these preparations is also carried out - as already mentioned in the case of shampoo - in a manner known per se with

25 addition of the active compound employed according to the invention. Of the abovementioned 1-hydroxy-2-pyridones, the preparations according to the invention can contain one compound or even several in combination.

The pH of the preparations is in the skin-physiological range of

30 approximately pH 4.5 to 6.5. Whereas, when using the compounds in salt form, the adjustment of the pH range mentioned has to be carried out using organic acids, this measure is not necessary when using the free compounds.

35 In the preparations according to the invention, the active compounds is incorporated in amounts which are customarily between approximately 0.05 and approximately 10%. Within this range, the concentrations of the specific preparations depend on their intended use. Certain preparation



forms such as concentrates, which are to be diluted before use, can have considerably higher concentrations.

If they are preparations which remain on the skin and on the scalp, for

5 example gel preparations, ointments, creams or hair lotions, lower concentrations will be employed, for example from about 0.05% to about 1%, preferably from 0.1 to 0.5%. In higher concentrations, they will expediently be used when they are preparations which, optionally after dilution, only act on the scalp for a short time, for example shampoos or liquid soaps. In

10 these cases, for example, concentrations of approximately 0.2 to approximately 10%, preferably from approximately 0.5% to approximately 2%, can be expedient.

The following quantitative data relate to the weight, if not stated otherwise.

15

Example 1

A preparation according to the invention has the following composition:

Shampoo

20 (based on anionic detergent substances)

1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone	1.00%
Sodium lauryl diglycol ether sulfate (27% strength solution)	40.00%
Disodium lauryl polyglycol ether sulfosuccinate (33% strength solution)	10.00%
Sodium chloride	2.50%
Water	46.50%



Example 2

A preparation according to the invention has the following composition:

Shampoo

5 (based on anionic detergent substance with amphoteric surfactant as cosurfactant)

1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone	1.00%
Sodium lauryl diglycol ether sulfate (27% strength solution)	36.00%
Cocamidopropylbetaine (30% strength solution)	6.00%
Sodium chloride	3.30%
Water	53.70%

10 Example 3

A preparation according to the invention has the following composition:

Shampoo

(based on anionic detergent substance with nonionic surfactant as cosurfactant)

1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone	1.50%
Sodium lauryl diglycol ether sulfate (27% strength solution)	30.00%
Lauryl alcohol polyglucoside	8.00%
Sodium chloride	2.00%
Water	58.50%



Example 4

A preparation according to the invention has the following composition:

Liquid soap	
5	
1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone	1.00%
Sodium lauryl diglycol ether sulfate (27% strength solution)	35.00%
Cocamidopropylglycol ether sulfate magnesium salt (30% strength solution)	8.00%
Cocamidopropylbetaine (30% strength solution)	10.00%
Lauryl alcohol glycol ether	2.00%
Sodium chloride	2.00%
Water	42.00%



Example 5

A preparation according to the invention has the following composition:

5	Hair lotion	
	1-Hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxy]methyl]-2(1H)pyridone	0.05%
	2-Propanol	60.00%
	Water	39.95%

Example 6

A preparation according to the invention has the following composition:

10	Gel preparation	
	1-Hydroxy-4-methylcyclohexyl-2(1H)pyridone	0.75%
	2-Propanol	15.00%
	2-Octyldodecanol	7.50%
	Carbomer 4,000,000	0.50%
	Polysorbate 60	1.50%
	Sodium hydroxide	0.18%
	Water	74.57%

Example 7

15 A preparation according to the invention has the following composition:

Cream preparation

15	1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)-pyridone, aminoethanol salt 1:1	1.00%
	2-Octyldodecanol	7.50%
	Liquid paraffin	7.50%
	Stearyl alcohol	7.50%
	Cetyl alcohol	7.50%
	Polysorbate 60	3.00%
	Sorbitan monostearate	2.00%
	Lactic acid, 90% strength	0.51%



Water	63.49%
-------	--------

Example 8

5 In a clinical study with a total of 180 patients, it was possible to show that the symptoms of seborrheic dermatitis of the scalp (severe scaling, inflammation, itching) can be effectively treated by a 1-2 x weekly treatment with a 1% strength ciclopirox shampoo preparation over a period of 4 weeks.

10 Example 9

In a clinical study, it was possible to successfully treat 180 patients with seborrheic dermatitis of the scalp, of the face and of the upper body by application of a 0.77% strength ciclopirox gel preparation over a period of 15 4 weeks.

The terms "comprise", "comprises", "comprised" and "comprising" when used in this specification are taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

The term "skin-physiological range" when used to refer to pH, means the range of about 4.5 – 6.5.


20
21
22
23
24

25
26
27
28




Patent claims:

1. The use of 1-hydroxy-2-pyridone of the formula I



In which R^1 , R^2 and R^3 , which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II



where

X is S or O,

Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine,

Z is a single bond or the bivalent radicals O, S, $-CR^2-$, in which R is H or (C_1-C_4) -alkyl, or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where - if the radicals contain 2 or more oxygen and/or sulfur atoms - the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C_1-C_4) -alkyl groups,

Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy,



AMENDED SHEET

(C₁-C₄)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form,

for the production of a medicated shampoo, comprising at least one anionic, cationic, nonionic or amphoteric surfactant or a mixture of the surfactants and which has a pH in the skin-physiological range, as hereinbefore defined, for the treatment of seborrheic dermatitis.

2. The use as claimed in claim 1, wherein the compound of the formula I is employed in which Ar is a bicyclic system which is derived from biphenyl, diphenylalkane or diphenyl ether.
3. The use as claimed in claim 1 or 2, wherein the compound of the formula I contains a cyclohexyl radical in the position R⁴.
4. The use as claimed in one or more of claims 1 to 3, wherein the compound of the formula I contains an octyl radical of the formula -CH₂-CH(CH₃)-CH₂-C(CH₃)₃ in the position R⁴.
5. The use as claimed in claim 1, wherein 1-hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxy]methyl]-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone is employed.
6. The use as claimed in claim 1, wherein the surfactant employed is at least one anionic surfactant on its own or as a mixture with other anionic surfactants and/or amphoteric surfactants.
7. The use as claimed in claim 1, wherein the 1-hydroxy-2-pyridone of the formula I is employed in a concentration of 0.2% to 10%.
8. The use as claimed in claim 7, wherein the 1-hydroxy-2-pyridone of the formula I is employed in a concentration of 0.5% to 2%.
9. The use as claimed in claim 1, wherein the medicated shampoo has a pH of approximately 4.5 to 6.5.



10. A method of treatment of seborrheic dermatitis comprising administration of 1-hydroxy-2-pyridone of the formula I as claimed in claim 1, in a medicated shampoo, comprising at least one anionic, cationic, nonionic or amphoteric surfactant or a mixture of surfactants and which shampoo has a pH in the skin-physiological range, as hereinbefore defined.

11. The method as claimed in claim 10, wherein the compound of the formula I is employed in which Ar is a bicyclic system which is derived from biphenyl, diphenylalkane or diphenyl ether.

12. The method as claimed in claim 10 or 11, wherein the compound of the formula I contains a cyclohexyl radical in the position R⁴.

13. The method as claimed in one or more of claims 10 to 12, wherein the compound of the formula I contains an octyl radical of the formula -CH₂-CH(CH₃)-CH₂-C(CH₃)₃ in the position R⁴.

14. The method as claimed in claim 10, wherein 1-hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxyethyl]-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone is employed.

15. The method as claimed in claim 10, wherein the surfactant employed is at least one anionic surfactant on its own or as a mixture with other anionic surfactants and/or amphoteric surfactants.

16. The method as claimed in claim 10, wherein the 1-hydroxy-2-pyridone of the formula I is employed in a concentration of 0.2% to 10%.

17. The method as claimed in claim 16, wherein the 1-hydroxy-2-pyridone of the formula I is employed in a concentration of 0.5% to 2%.



18. The method as claimed in claim 10, wherein the medicated shampoo has a pH of approximately 4.5 to 6.5.

DATED this 6th day of December 1999
HOECHST AKTIENGESELLSCHAFT

WATERMARK PATENT AND TRADEMARK ATTORNEYS
290 BURWOOD ROAD
HAWTHORN VICTORIA 3122

KJS:KMH:VRH P8330AU00.DOC

3
2
1
0
9
8
7
6

